Guideline on the requirements of external quality assessment programs in molecular pathology

Abstract

Molecular pathology is an integral part of daily diagnostic pathology and used for classification of tumors, for prediction of prognosis and response to therapy, and to support treatment decisions. For these reasons, analyses in molecular pathology must be highly reliable and hence external quality assessment (EQA) programs are called for. Several EQA programs exist to which laboratories can subscribe, but they vary in scope, number of subscribers, and execution. The guideline presented in this paper has been developed with the purpose to harmonize EQA in molecular pathology. It presents recommendations on how an EQA program should be organized, provides criteria for a reference laboratory, proposes requirements for EQA test samples, and defines the number of samples needed for an EQA program. Furthermore, a system for scoring of the results is proposed as well as measures to be taken for poorly performing laboratories. Proposals are made regarding the content requirements of an EQA report and how its results should be communicated. Finally, the need for an EQA database and a participant manual are elaborated. It is the intention of this guideline to improve EQA for molecular pathology in order to provide more reliable molecular analyses as well as optimal information regarding patient selection for treatment.

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

“…For predictive testing in NSCLC, reports have been published for EGFR 40–42 and KRAS 42 mutational analysis, and ALK 4344 Guidelines for standardisation of EQA schemes have recently been introduced 45…”

KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond

“…The results of the first round of the ESP assessment, conducted in 59 laboratories of 8 European countries, revealed that only 70% of laboratories correctly genotyped all samples 52. Three aspects of molecular testing were assessed: the percentage of neoplastic cells in the specimen, the molecular test itself and reporting, as recommended by van Krieken et al 52 109 Because the correct mutation call rate decreases in proportion to the decreasing percentage of tumour cells in a specimen, quality assurance programmes should include samples with a low tumour content 110. To this aim, artificial paraffin blocks consisting of mutation-positive colorectal cancer cells diluted in a background of mutation phase are useful 111.…”

Guidance for laboratories performing molecular pathology for cancer patients

“…Methods to individualise the status of a tumour include immunohistochemistry, and molecular pathology, which is generally taken to mean the analysis of nucleic acids from tissue, cells or fluids. 2 Molecular testing is therefore becoming an essential part of the work-up for many if not most patients with solid and haematological tumours. As a consequence, most hospitals with an active oncology practice require access to laboratories that provide the necessary information on the genetic make-up of a tumour from biopsy material.…”